|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 帕博利珠单抗治疗伴脑转移NSCLC患者的一项非随机、开放Ⅱ期试验的长期随访结果和生物标志物分析显示文摘背景与目的我们开展了一项帕博利珠单抗用于伴未治疗脑转移的非小细胞肺癌(non-small cell lung cancer,NSCLC)或黑色素瘤患者的疗效和安全性的II期试验,旨在评估程序性死亡受体1(programmed cell death 1,PD-1)抑制剂在中枢神经系统(central nervous system,CNS)中的疗效。中期结果已发表,现报道对NSCLC队列的更新分析结果。方法这是一项开放性、单中心、II期试验。纳入标准:年龄≥18岁,诊断为晚期NSCLC并伴有≥1个5 mm-20 mm脑转移病灶,既往从未治疗或之前放疗后进展,无神经系统症状,不需要激素治疗且美国东部肿瘤协作组(Eastern Cooperative Oncology Group,ECOG)<2分。患者每2周接受一次帕博利珠单抗(10 mg/kg)治疗。队列1为程序性死亡配体1(programmed cell death ligand 1,PD-L1)≥1%的患者,队列2为PD-L1<1%或未评估的患者。主要终点是脑转移患者缓解比例。所有经治患者均纳入疗效与安全性终点的分析。该研究已结束入组,并于Clinicaltrials.gov登记注册,注册号为NCT02085070。结果2014年3月31日-2018年5月21日,共42例患者接受治疗。中位随访时间为8.3个月(IQR:4.5个月-26.2个月)。队列1的37例患者中11例有脑转移缓解[29.7%(95%CI:15.9%-47.0%)]。队列2未观察到缓解。治疗相关的3级-4级不良事件(adverse events,AEs)包括2例肺炎、1例全身症状、1例结肠炎、1例肾上腺皮质功能不全、1例高血糖症和1例低钾血症。6例(14%)患者发生了治疗相关的严重不良事件,包括肺炎、急性肾损伤、低钾血症和肾上腺皮质功能不全。没有观察到治疗相关死亡病例。结论帕博利珠单抗治疗PD-L1≥1%的NSCLC伴脑转移患者有效,且对所有纳入的未经治疗的脑转移患者安全。需要进一步探索免疫治疗用于NSCLC合并CNS转移。 | Sarah B GOLDBERG Kurt A SCHALPER Scott N GETTINGER Amit MAHAJAN Roy S HERBST Anne C CHANG Rogerio LILENBAUM Frederick H WILSON Sacit Bulent OMAY James B YU Lucia JILAVEANU Thuy TRAN Kira PAVLIK Elin ROWEN Heather GERRSH Annette KOMLO Richa GUPTA Hailey WYATT Matthew RIBEIRO Yuval KLUGER Geyu ZHOU Wei WEI Veronica L CHANG Harriet M KLUGER 董晓荣(翻译/校对) | 2021 | 中国肺癌杂志2021，24，9： | 34 |
| 2 | Retrograde-viewing device improves adenoma detection rate in colonoscopies for surveillance and diagnostic workup显示文摘AIM:To determine which patients might benefit most from retrograde viewing during colonoscopy through subset analysis of randomized,controlled trial data.METHODS:The Third Eye Retroscope Randomized Clinical Evaluation(TERRACE) was a randomized,controlled,multicenter trial designed to evaluate the efficacy of a retrograde-viewing auxiliary imaging device that is used during colonoscopy to provide a second video image which allows viewing of areas on the proximal aspect of haustral folds and flexures that are difficult to see with the colonoscope's forward view.We performed a post-hoc analysis of the TERRACE data to determine whether certain subsets of the patient population would gain more benefit than others from use of the device.Subjects were patients scheduled for colonoscopy for screening,surveillance or diagnostic workup,and each underwent same-day tandem examinations with standard colonoscopy(SC) and Third Eye colonoscopy(TEC),randomized to SC followed by TEC or vice versa.RESULTS:Indication for colonoscopy was screening in 176/345 subjects(51.0%),surveillance after previous polypectomy in 87(25.2%) and diagnostic workup in 82(23.8%).In 4 subjects no indication was specified.Previously reported overall results had shown a net additional adenoma detection rate(ADR) with TEC of 23.2% compared to SC.Relative risk(RR) of missing adenomas with SC vs TEC as the initial procedure was 1.92(P = 0.029).Post-hoc subset analysis shows additional ADRs for TEC compared to SC were 4.4% for screening,35.7% for surveillance,55.4% for diagnostic and 40.7% for surveillance and diagnostic combined.The RR of missing adenomas with SC vs TEC was 1.11(P = 0.815) for screening,3.15(P = 0.014) for surveillance,8.64(P = 0.039) for diagnostic and 3.34(P = 0.003) for surveillance and diagnostic combined.Although a multivariate Poisson regression suggested gender as a possibly significant factor,subset analysis showed that the difference between genders was not statistically significant.Age,bowel prep quality and withdrawal time did not significantly affect the RR of missing adenomas with SC vs TEC.Mean sizes of adenomas detected with TEC and SC were similar at 0.59 cm and 0.56 cm,respectively(P = NS).CONCLUSION:TEC allows detection of significantly more adenomas compared to SC in patients undergoing surveillance or diagnostic workup,but not in screening patients(ClinicalTrials.gov Identifier:NCT01044732). | Peter D Siersema Amit Rastogi Anke M Leufkens Paul A Akerman Kassem Azzouzi Richard I Rothstein Frank P Vleggaar Alessandro Repici Giacomo Rando Patrick I Okolo Olivier Dewit Ana Ignjatovic Elizabeth Odstrcil James East Pierre H Deprez Brian P Saunders Anthony N Kalloo Bradley Creel Vikas Singh Anne Marie Lennon Daniel C DeMarco | 2012 | World Journal of Gastroenterology2012，18，26： | 6 |
| 3 | Deep learning in hepatocellular carcinoma:Current status and future perspectives显示文摘Hepatocellular carcinoma(HCC)is among the leading causes of cancer incidence and death.Despite decades of research and development of new treatment options,the overall outcomes of patients with HCC continue to remain poor.There are areas of unmet need in risk prediction,early diagnosis,accurate prognostication,and individualized treatments for patients with HCC.Recent years have seen an explosive growth in the application of artificial intelligence(AI)technology in medical research,with the field of HCC being no exception.Among the various AI-based machine learning algorithms,deep learning algorithms are considered state-of-the-art techniques for handling and processing complex multimodal data ranging from routine clinical variables to high-resolution medical images.This article will provide a comprehensive review of the recently published studies that have applied deep learning for risk prediction,diagnosis,prognostication,and treatment planning for patients with HCC. | Joseph C Ahn Touseef Ahmad Qureshi Amit G Singal Debiao Li Ju-Dong Yang | 2021 | World Journal of Hepatology2021，13，12： | 2 |
| 4 | Clinical outcomes of endoscopic management of pancreatic fluid collections in cirrhotics vs non-cirrhotics: A comparative study显示文摘BACKGROUND Endoscopic management of symptomatic pancreatic fluid collections (PFCs) using self-expandable metal stents (SEMS) placement has emerged as an innovative therapeutic approach with excellent efficacy, safety, and relatively few adverse outcomes. However, their use has not been studied in patients with cirrhosis. Cirrhotics tend to be considered less than optimal candidates due to concern for portal hypertension and coagulopathy related complications. AIM To compare the efficacy and safety of using SEMS for drainage of symptomatic PFCs in cirrhotic vs non-cirrhotic patients. METHODS We conducted a retrospective comparative analysis of patients with symptomatic PFCs [pancreatic pseudocyst (PP) or walled-off necrosis (WON)] who underwent endoscopic ultrasound (EUS)-guided placement of fully covered self-expandable metals stents or lumen-apposing self-expandable metal stents. All patients were followed clinically until resolution of PFCs or death. Definition:(1) Technical success was defined as successful placement of SEMS;and (2) Clinical success was defined as complete resolution of the PFCs without additional interventions including interventional radiology or surgery. Number of procedures performed per patient, number of patients who achieved complete resolution of the PFCs without additional interventions and procedure related adverse events were recorded.RESULTS From January 2012 to December 2017, a total of 88 patients underwent EUSguided drainage of symptomatic PFCs. Of these, 58 non cirrhotic patients underwent plastic stent insertion for management of PFC and 30 patients, 5 with cirrhosis and 25 without cirrhosis, underwent EUS-guided transmural drainage with SEMS, including 18 (60%) PP and 12 (40%) WON. Technical success was achieved in all 30 patients. Clinical success was achieved in 60% cirrhotic patients and 92% non-cirrhotics (P = 0.12). Procedure-related adverse events were 60% in cirrhotic and 28% non-cirrhotic (P = 0.62). Moreover, fatal adverse events were statistically more common in cirrhotics compared with non-cirrhotics (0 vs 40%;P = 0.023). Successful stent removal following resolution of the PFC, was 60% in cirrhotics and 80% in non-cirrhotics (P = 0.57). Post-procedure length of hospitalization was 18.6 ± 20.3 d in cirrhotics and 5.6 ± 13.7 d in non-cirrhotics (P = 0.084). CONCLUSION EUS-guided management of PFC using SEMS placement has a high technical and clinical success rate in non-cirrhotics. However, in cirrhotics caution must be exercised given the high morbidity and mortality as evidenced by our cohort, particularly for the endoscopic debridement of WONs. Larger, multicenter studies are warranted to further characterize the risk profile and outcomes in these patients. | Sobia Laique Matheus C Franco Tyler Stevens Amit Bhatt John J Vargo Prabhleen Chahal | 2019 | World Journal of Gastrointestinal Endoscopy2019，11，6： | 2 |
| 5 | Dynamic power management in wireless sensor networks 显示文摘 | AMIT S ANANTHA C | 2001 | Selected Test of Comput- er2001，18，2： | 1 |
| 6 | Business model innovation: creating value in times of change 显示文摘 | ZOTT C AMIT R | 2009 | Universia Business Review2009，，23： | 1 |
| 7 | Business model design and the performance of entrepreneurial firms 显示文摘 | ZOTT C AMIT R | 2007 | Organization Science2007，18，2： | 1 |
| 8 | Value Creation in E-business显示文摘 | Amit R Zott C | 2001 | Strategic Management Journal2001，22，6： | 1 |
| 9 | The business model: A theoretically anchored robust construct for strategic analysis 显示文摘 | Zott C Amit R | 2013 | Strategic Organization2013，11，4： | 1 |
| 10 | Acute bleeding after argon plasma coagulation for weight regain after gastric bypass: A case report显示文摘Roux-en-Y gastric bypass(RYGB)is the most commonly performed surgical procedure used to treat obesity worldwide.Despite satisfactory results in terms of weight loss,over time many patients experience weight regain.There are many factors that contribute to weight regain after RYGB,including the diameter of the gastric-jejunal anastomosis(GJA).One of the most commonly performed endoscopic procedures for weight regain after RYGB is argon plasma coagulation(APC).We report a case of hematemesis after outlet revision with APC.We highlight several treatment modalities that can be used to treat this complication.CASE SUMMARY A 45-year-old female with a history of weight regain after RYGB was referred for possible endoscopic treatment for weight regain.On endoscopic evaluation,the diameter of the GJA was 22 mm.Due to the dilated GJA,treatment with APC was performed.Several months later she reported a return of poor satiety and an increased appetite.A repeat endoscopy was then performed.The GJA was approximately 15 mm and was incompetent.APC was performed.One day post procedure she had four episodes of hematemesis.An endoscopy was performed and a large ulcer with a visible arterial vessel was visualized at the GJA.Coagulation was attempted using a Coagrasper and after initial contact with the vessel,the vessel started oozing.Due to fibrosis and the depth of ulceration in the area,clips and repeat APC could not be used.Therefore,an attempt to inject epinephrine injection was made.However,persistent oozing was noted.As a result,hemostatic powder was applied to the region of the bleeding vessel.Subsequently,no more bleeding was observed.On follow-up,the patient remained hemodynamically stable and a second look endoscopy was not performed.The patient was discharged three days later.CONCLUSION APC revision of the GJA is known to be a relatively safe and effective strategy to manage weight regain post RYGB.Anastomotic site bleeding is an infrequent and potentially life-threatening complication associated with this therapy.Endoscopic management is the first line therapy used to achieve hemostasis in these cases. | Diogo Turiani Hourneaux de Moura Amit H Sachdev Po-Wen Lu Igor Braga Ribeiro Christopher C Thompson | 2019 | World Journal of Clinical Cases2019，7，15： | 1 |
| 11 | The fit between product market strategy and Business model : implications for firm performance 显示文摘 | zorfT C AMIT R | 2008 | Strategic Management Journal2008，29，1： | 1 |
| 12 | The business model: Recent developments and future research显示文摘 | Zott C Amit R Massa L | 2011 | Journal of Manage- ment2011，37，4： | 1 |
| 13 | Value creation in e-business 显示文摘 | Amit R Zott C | 2001 | Strategic Management Journal2001，22，67： | 1 |
| 14 | Business model design: an activity system perspective 显示文摘 | ZOTY C AMIT R | 2010 | Long Range Planning2010，43，2： | 1 |
| 15 | Business model design: an activity system per- spective显示文摘 | ZOTT C AMIT R | 2010 | Long Range Planning2010，43，1： | 1 |
| 16 | The business model: A theoretically anchored robust construct for strategic analysis显示文摘 | Zott C Amit R | 2013 | Stra- tegic Organization2013，11，4： | 1 |
| 17 | Creating value through business model innovation显示文摘 | Amit R Zott C | 2012 | MIT Sloan Management Review2012，53，3： | 1 |
| 18 | Ethanol metabolism in rat brain homogenates by a catalase-H202 system显示文摘 | ARAGON C M ROGAN F AMIT Z | 1992 | Biochem Pharmacol1992，44，： | 1 |
| 19 | Value Creation in e -Business 显示文摘 | Amit R Zott C | 2001 | Strategic Management Journal2001，22，67： | 1 |
| 20 | Designing your future business model: An activity system perspective显示文摘 | Zott C and Amit R | 2010 | Long Range Planning2010，43，23： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员